Prolactin receptor antagonist - Oncolix

Drug Profile

Prolactin receptor antagonist - Oncolix

Alternative Names: Prolanta

Latest Information Update: 26 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Oncolix
  • Class Hormones; Pituitary gonadotropins
  • Mechanism of Action Prolactin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Preclinical Breast cancer

Most Recent Events

  • 26 Apr 2016 Prolanta™ receives Orphan Drug status for Ovarian cancer in USA prior to this date
  • 01 Feb 2016 Phase-I clinical trials in Fallopian tube cancer (Recurrent, Second-line therapy or greater) in USA (SC) (NCT02534922)
  • 01 Feb 2016 Phase-I clinical trials in Ovarian cancer (Recurrent, Second-line therapy or greater) in USA (SC) (NCT02534922)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top